Invariant natural killer T-cell receptor–CD1d–alpha-galactosylceramide complex (iNKT TCR–CD1d–α-GalCer)

The Invariant natural killer T-cell receptor–CD1d–alpha-galactosylceramide (iNKT TCR–CD1d–α-GalCer) complex is a specialized immunological assembly that plays a pivotal role in bridging innate and adaptive immunity [1]. This complex forms when the semi-invariant T-cell receptor (TCR) of an iNKT cell recognizes the glycolipid antigen alpha-galactosylceramide (α-GalCer) presented by the MHC class I-like molecule CD1d on antigen-presenting cells [2]. The formation of this ternary interface triggers rapid and robust activation of iNKT cells, resulting in the immediate secretion of a broad spectrum of cytokines, including interferon-gamma (IFN-γ) and interleukin-4 (IL-4) [3]. These cytokines subsequently activate other immune effectors such as natural killer (NK) cells, dendritic cells, and cytotoxic T lymphocytes, creating a potent anti-tumor or antimicrobial environment [1]. In clinical settings, synthetic agonists like α-GalCer (KRN7000) and its derivatives are used to target this interface to treat malignancies and infectious diseases [4]. However, a significant therapeutic challenge is the induction of iNKT cell anergy following strong TCR stimulation, which can limit the effectiveness of repeated dosing [5].

Other names

CD1d–α-GalCer–TCR complexiNKT cell activation complexCD1d-glycolipid-TCR interfaceTCR-CD1d-alpha-GalCer ternary complex

Agonist-induced formation of a ternary complex between the iNKT TCR and CD1d-lipid, leading to downstream signaling and rapid cytokine release.